SELLAS Life Sciences (SLS) Acquisitions (2013 - 2014)

SELLAS Life Sciences (SLS) posted quarterly Acquisitions of $100000.0 for Q4 2014, down 67.21% quarter-over-quarter from $305000.0 in Q2 2014.

SELLAS Life Sciences (SLS) Acquisitions (2013 - 2014) Analysis & Trends

SELLAS Life Sciences (SLS) has reported Acquisitions for 2 consecutive years, with $100000.0 the latest figure, recorded in Q4 2014.

In Q4 2014, Acquisitions changed N/A year-over-year to $100000.0; the TTM figure through Sep 2015 stood at $100000.0 (down 95.68% YoY), while the FY2017 annual figure was $12.2 million, changed N/A from the prior year.
Acquisitions slipped to $100000.0 in Q4 2014 per SLS's latest filing, from $305000.0 in the prior quarter.
Across five years, Acquisitions topped out at $10.1 million in Q1 2013 and bottomed at $100000.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	SELLAS Life Sciences	2.32 Bn	2.18 Bn	-	-

Download Data